Alzheimer's disease: from bench side to bed side
Drug systematic administration to brain is challenged by blood–brain barrier (BBB). Only small lipophilic drugs cross BBB. Nearly 100% of biologics cannot cross BBB. Biologics composed 33% of FDA-approved drugs in 2019. Nanoparticles were used to cross BBB after suitable surface modification with mo...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Conference or Workshop Item |
| Language: | English English English English English |
| Published: |
2020
|
| Subjects: | |
| Online Access: | http://irep.iium.edu.my/88240/2/BNC%202020%20Hi5%202020%20Dr%20Abd%20Almonem.pdf http://irep.iium.edu.my/88240/14/Hi5%202020_Tentative_Final_29%20NOV%202020.pdf http://irep.iium.edu.my/88240/15/E%20PROGRAM%20BOOK%20BNC%20Hi5%20Retreat%202020.pdf http://irep.iium.edu.my/88240/17/Translational%20Forum%20Invitation%20Letter_%20Dr%20Wael%20et%20al.pdf http://irep.iium.edu.my/88240/16/01%20Cert_Hi5_Attendance.pdf http://irep.iium.edu.my/88240/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Drug systematic administration to brain is challenged by blood–brain barrier (BBB). Only small lipophilic drugs cross BBB. Nearly 100% of biologics cannot cross BBB. Biologics composed 33% of FDA-approved drugs in 2019. Nanoparticles were used to cross BBB after suitable surface modification with molecules to recognize receptors on BBB. |
|---|